Evidence map›Paper›PMID 26342026›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2015

New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.

Jean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, Jaroslav Jelinek, Steven H Lin, William N William, Mitchell J Frederick, Jing Wang, Wenhua Lang, Lei Feng and 11 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Global analysis of DNA methylation changes during experimented lingual carcinogenesis.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Jean-Philippe FoyCancer Research Center of Lyon, UMR INSERM 1052-CNRS 5286, Lyon, France. Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France. Department of Oral and Maxillo-Facial Surgery, Hôpital Pitié Salpêtrière, Paris, France.
Curtis R PickeringDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vassiliki A PapadimitrakopoulouDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jaroslav JelinekFels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania.
Steven H LinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
William N WilliamDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mitchell J FrederickDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wenhua LangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Li ZhangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edward S KimLevine Cancer Institute, Carolinas Health Care System, Charlotte, North Carolina.
You H FanDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Waun K HongDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adel K El-NaggarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jean-Pierre IssaFels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania.
Scott M LippmanUC San Diego Moores Cancer Center, San Diego, California. pierre.saintigny@lyon.unicancer.fr LMao@umaryland.edu slippman@ucsd.edu.
Li MaoOncology and Diagnostic Science, University of Maryland Dental School, Baltimore, Maryland. pierre.saintigny@lyon.unicancer.fr LMao@umaryland.edu slippman@ucsd.edu.
Pierre SaintignyCancer Research Center of Lyon, UMR INSERM 1052-CNRS 5286, Lyon, France. Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France. Department of Medicine, Centre Léon Bérard, Lyon, France. Université de Lyon, Lyon, France. pierre.saintigny@lyon.unicancer.fr LMao@umaryland.edu slippman@ucsd.edu.
The University of Texas MD Anderson Cancer Center · USTemple University · USCarolinas Healthcare System · USCentre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FRUniversity of Maryland, Baltimore · USUniversity of San Diego · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS P50 CA97007
6 · The paper itself

Abstract

DNA promoter methylation of tumor suppressor genes and global DNA hypomethylation are common features of head and neck cancers. Our goal was to identify early DNA methylation changes in oral premalignant lesions (OPL) that may serve as predictive markers of developing oral squamous cell carcinoma (OSCC). Using high-throughput DNA methylation profiles of 24 OPLs, we found that the top 86 genes differentially methylated between patients who did or did not develop OSCC were simultaneously hypermethylated, suggesting that a CpG island methylation phenotype may occur early during OSCC development. The vast majority of the 86 genes were nonmethylated in normal tissues and hypermethylated in OSCC versus normal mucosa. We used pyrosequencing in a validation cohort of 44 patients to evaluate the degree of methylation of AGTR1, FOXI2, and PENK promoters CpG sites that were included in the top 86 genes and of LINE1 repetitive element methylation, a surrogate of global DNA methylation. A methylation index was developed by averaging the percent methylation of AGTR1, FOXI2, and PENK promoters; patients with a high methylation index had a worse oral cancer-free survival (P = 0.0030). On the other hand, patients with low levels of LINE1 methylation had a significantly worse oral cancer-free survival (P = 0.0153). In conclusion, AGTR1, FOXI2, and PENK promoter methylation and LINE1 hypomethylation may be associated with an increased risk of OSCC development in patients with OPLs.

Indexed as

DNA MethylationCarcinoma, Squamous CellCell LineCpG IslandsDisease-Free SurvivalDisease ProgressionFemaleFollow-Up StudiesHumansMaleMouth NeoplasmsPhenotypePrecancerous ConditionsPromoter Regions, GeneticProportional Hazards ModelsReceptor, Angiotensin, Type 1AGTR1 protein, humanReceptor, Angiotensin, Type 1

Identifiers

PMID26342026
PMCPMC4777304
OpenAlexW2107880877

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.